Lydia Shotton is an experienced EU policy professional specialising in ATMPs, including cell and gene therapies. As the European policy lead at the Alliance for Regenerative Medicine (ARM), Lydia drives the organisation’s engagement with EU institutions and key stakeholders to shape policies that enable innovation, access, and investment in next-generation medicines.

She works at the intersection of healthcare policy, life sciences innovation, and patient access, bringing a cross-sector perspective that connects policymakers with the realities of scientific advancement and unmet medical need. Lydia has led strategic initiatives on regulatory reform, market access, and health system readiness for ATMPs, and regularly moderates high-level roundtables with regulators, industry leaders, patients, and clinicians.

With a strong track record in building coalitions and communicating complex issues clearly, Lydia is a trusted voice in Brussels on Europe’s future in advanced therapies.